|
Study
|
Histology
|
SCC (%)
|
Treatment
|
n
|
MS (months)
|
5-year OS (%)
|
P value
|
|---|
|
Pouliquen and colleagues [46]
|
SCC
|
100
|
CF
|
52
|
13
| |
NS
|
| | | |
Surgery
|
68
|
14
| | |
|
Ando and colleagues [47]
|
SCC
|
100
|
CV
|
100
| |
45
|
NS
|
| | | |
Surgery
|
105
| |
48
| |
|
Ando and colleagues [25]
|
SCC
|
100
|
CF
|
120
| |
61
|
NS
|
| | | |
Surgery
|
122
| |
52
| |
- CF cisplatin + fluorouracil, CV cisplatin + vindesine, MS median survival, NS not significant, OS overall survival, SCC squamous cell carcinoma.
